Exhibit 99.2
EXECUTION VERSION
SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT
This SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) dated January 12, 2022 is by and among Surgalign Holdings, Inc., a Delaware Corporation (“Buyer”), Roboticine, Inc, a Delaware corporation (“Seller”), Holo Surgical S.A., a Polish joint-stock company (“Holo S.A.”), Pawel Lewicki, PhD (“Lewicki”) and Krzysztof Siemionow, MD, PhD (“Siemionow”). Buyer, Seller, Holo S.A., Lewicki and Siemionow will each be referred to herein from time to time as a “Party” and, collectively, as the “Parties.”
RECITALS
WHEREAS, the Parties entered into that certain Stock Purchase Agreement (the “Original Agreement”), dated September 29, 2020, pursuant to which, among other things, Buyer agreed to purchase from Seller, and Seller agreed to sell to Buyer, all of the Shares, on the terms and subject to the conditions contained in the Purchase Agreement;
WHEREAS, the Parties entered into that certain First Amendment to Stock Purchase Agreement, dated October 23, 2020 (together with the Original Agreement, the “Purchase Agreement”); and
WHEREAS, the Parties desire to amend the Purchase Agreement as set forth herein in accordance with Section 12.09 of the Purchase Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the Parties hereby agree as follows:
AGREEMENTS
1. Defined Terms. Capitalized terms used and not otherwise defined herein have the meanings set forth in the Purchase Agreement.
2. Amendments to Purchase Agreement.
(a) The definition of “Buyer Sale” in Section 1.01 of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:
“means any one of the following, whether in one or a series of transactions, directly or indirectly: (i) the consummation of a merger or consolidation of Buyer with or into another Person (except a merger or consolidation in which Buyer is the surviving or resulting Person); or (ii) a sale, transfer or other disposition of the Group Companies or all or substantially all of the assets of the Group Companies on a consolidated basis, except where such sale, transfer or other disposition is to a direct or indirect wholly owned Subsidiary of Buyer.”
(b) Section 2.05(a)(i) of the Purchase Agreement is hereby amended and restated in its entirety to read as follows:
“Buyer shall issue or pay to Seller the 510(k) Earnout Consideration, subject to reduction pursuant to Section 2.05(d), if the 510(k) Clearance is obtained on or prior to April 30, 2022; provided, however, that if the 510(k) Clearance is not obtained on or prior to April 30, 2022, no 510(k) Earnout Consideration shall be payable under this Agreement; provided, further, that once the 510(k) Earnout Consideration is issued and/or paid by Buyer to Seller, Buyer shall have no further obligations pursuant to this Section 2.05(a)(i);”